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Volume 6Available online 13 July 2021Background: Patients with advanced gastrointestinal stromal tumours (GISTs) resistant to the tyrosine kinase inhibitors
imatinib and sunitinib may be treated with regorafenib, which resulted in a median progression-free survival (PFS) of
4.8 months in the GRID trial. Also, pazopanib, another tyrosine kinase inhibitor, has been studied in a randomized,
placebo-controlled trial (PAZOGIST) in the third line, which showed a PFS of 45.2% 4 months after study entry, but
patients intolerant to sunitinib were also included. We designed another trial evaluating pazopanib, enrolling only
patients with progression on both imatinib and sunitinib.
Patients and methods: Since all eligible patients had progressive disease, we preferred a non-randomized, phase II
multicentre trial so that all patients could receive a potentially active drug. Patients had a progressive metastatic or
locally advanced GIST and were 18 years of age, with a performance status of 0-2, and sufficient organ functions.
The primary endpoint was disease control rate (defined as complete remission þ partial remission þ stable disease)
at 12 weeks on pazopanib. A Simon’s two-stage analysis was used with an interim analysis 12 weeks after
enrollment of the first 22 patients, and if passed, there was a full enrolment of 72 patients. GIST mutational
analysis was done, and most patients had pazopanib plasma concentration measured after 12 weeks.
Results: Seventy-two patients were enrolled. The disease control rate after 12 weeks was 44%, and the median PFS was
19.6 weeks (95% confidence interval 12.6-23.4 weeks). Pazopanib-related toxicity was moderate and manageable. No
statistically significant differences were found related to mutations. Plasma concentrations of pazopanib had a formal
but weak correlation with outcome.
Conclusion: Pazopanib given in the third line to patients with GIST progressing on both imatinib and sunitinib was
beneficial for about half of the patients. The PAGIST trial confirms the results from the PAZOGIST trial, and the
median PFS achieved seems comparable to the PFS achieved with regorafenib in the third-line setting.
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Gastrointestinal stromal tumour (GIST) is the most common
mesenchymal tumour of the gastrointestinal tract, and one
of the most common types of soft tissue sarcomas. Beforeondence to: Associated Prof. Mikael Eriksson, Department of
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- Issue 4 - 2021the millennium shift, there was no effective treatment of
metastatic or locally advanced non-operable GIST, and the
prognosis was poor.
Tyrosine kinase inhibitors (TKIs) have been established as
an effective treatment of the majority of GIST patients for
almost 20 years.1,2 Imatinib is approved for both advanced
non-operable disease and for adjuvant use in high-risk pa-
tients.3 It is also used frequently in the preoperative setting
to facilitate surgery. Sunitinib is approved for advanced GIST
when the disease progresses on imatinib or when the pa-
tient does not tolerate that drug,4 and regorafenib is
approved in the third line.5https://doi.org/10.1016/j.esmoop.2021.100217 1
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cancer and non-GIST soft tissue sarcoma.6,7 The spectrum of
target kinases resembles those for sunitinib and regor-
afenib, including the receptor tyrosine kinases KIT, PDGFRA,
and VEGF 1-3. However, pazopanib does have less
burdensome skin and mucosal toxicity as shown in clinical
practice. The similarity between these TKIs makes it relevant
to investigate the effect of pazopanib in advanced GIST. In
advanced GIST, TKIs are often used in more than three lines,
if available. All TKIs are different and any new TKI may be
beneficial for a GIST patient.
The PAZOGIST trial on pazopanib, which included pa-
tients after imatinib and sunitinib failure, showed a
progression-free survival (PFS) of 45.2% after 4 months
from the date of randomization, but some of them may
have had a more indolent course since not only patients
with progressing disease, but also patients who were
intolerant to sunitinib were included.8
In most studies on advanced GIST in the third-line setting
or beyond, patient eligibility has not only been progressive
disease during an earlier TKI treatment, but also encom-
passed non-tolerance for the on-going drug. Tolerance is,
however, a relative conception. Side-effects may often be
ameliorated with symptom-relieving drugs or by reduction
of the dose, and even markedly reduced doses have often
been shown to be effective enough to control the disease.
Patients who terminated the previous treatment due to
intolerance may not have resistant disease. We wanted to
specifically investigate whether patients progressing on
both imatinib and sunitinib at their highest tolerable doses
could benefit from treatment with pazopanib. Patients who
had also been treated with nilotinib, earlier evaluated for
GIST, were also eligible provided that they had progressed
during all three mentioned TKIs. Most of these patients had
participated in a first-line trial compared with imatinib.
A GIST in progression leads to a very poor PFS without
treatment, and thus also on placebo, shown in all placebo-
controlled trials in advanced GIST so far. We therefore
decided to investigate pazopanib in a phase II single-arm trial.
PATIENTS AND METHODS
A non-comparative, single-arm phase II trial was carried out
at selected sites in five countries (Sweden, Germany, Nor-
way, Finland and Denmark).
The trial (SSG XXI, PAGIST) was sponsored by the Scan-
dinavian Sarcoma Group (SSG), and it was approved by the
Institutional Review Boards/Ethical Boards in the partici-
pating countries. All patients signed a written informed
consent form.
This trial was registered at ClinicalTrials.gov website with
an identifier NCT01524848, and had a European Union Drug
Regulating Authorities Clinical Trials (EudraCT) number
2011-004404-37.Eligibility criteria
Eligible patients had locally advanced or metastatic histo-
logically and/or genetically proven GIST, as confirmed by a2 https://doi.org/10.1016/j.esmoop.2021.100217specialized sarcoma pathologist, and had measurable dis-
ease according to the RECIST.9 Patients were required to
have a history of progressive disease according to the
RECIST 1.1 criteria after both imatinib and sunitinib treat-
ment, and also on nilotinib if this drug had been used. No
other TKIs were allowed as earlier treatments. Age was
required to be at least 18 years at the time of the diagnosis
of GIST, and the World Health Organization (WHO) perfor-
mance status (PS) at inclusion 0-2. All side-effects from
earlier TKI treatments must have been subsided to Grade 1
or 0. Sufficient organ functions of the bone marrow, liver,
kidneys and heart were mandatory, and no serious
comorbidities as specified in the study protocol were
allowed. Pregnant or lactating women were not eligible. For
further details, see the complete SSG XXI protocol which is
available on the SSG website.10
Treatment and assessments
Eligible patients started on pazopanib (Votrient®) at 800 mg
daily, between meals, with strict criteria for dose reductions
in case of toxicity. The treatment was continued until any of
the following events occurred: progressive disease accord-
ing to RECIST 1.1, unacceptable toxicity defined as grade 3-4
adverse events occurring at the dose level of 400 mg,
intercurrent conditions contraindicating further pazopanib,
or patient’s preference.
Within 14 days before treatment start, a computed to-
mography (CT) scan of the thorax, abdomen, and pelvic
region was carried out, and CT of the abdomen/pelvic re-
gion (and thorax only if involved at baseline) was repeated
at treatment week 12 and thereafter every 8 weeks as long
as the treatment continued, or earlier if clinically indicated.
At baseline, a physical examination including blood
pressure and assessment of PS was carried out, compre-
hensive laboratory testing was done, and electrocardiog-
raphy was also included. All these examinations were
repeated at weeks 4, 8, 12 and every 8 weeks thereafter
during the whole treatment period. At baseline, a preg-
nancy test was also done for women with childbearing
potential.
Left ventricular ejection fraction was assessed by echo-
cardiography or multigated acquisition (MUGA) scintigraphy
at baseline, at week 12 and every 16 weeks thereafter.
Follow-up was done until 30 days after the end of
treatment of all patients. Thus, the trial ended 30 days after
the end of treatment of the last patient since overall sur-
vival was not an endpoint to be followed.
One blood sampling for plasma concentration of pazo-
panib was done at week 12 on treatment, and the mea-
surement was carried out at the PPD Laboratories, Madison,
WI, USA.
For further details, see the complete SSG XXI protocol
which is available on the SSG website.10
Study endpoints
The primary endpoint was defined as disease control rate
(DCR) at 12 weeks after treatment start according to RECISTVolume 6 - Issue 4 - 2021
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GIST, gastrointestinal stromal tumour; WHO, World Health Organization.
M. Eriksson et al. ESMO Openversion 1.1.9 DCR was defined as complete remission þ
partial remission (PR) þ stable disease (SD).
Secondary endpoints encompassed PFS, overall response
rate (ORR), DCR in relation to mutational status, DCR in
relation to plasma concentration at week 12, and toxicity
measured with Common Terminology Criteria for Adverse
Events (CTCAE) version 4.0.11
Statistics
For the primary endpoint, DCR, Simon’s two-stage analysis
was used.12 The study tested the null hypothesis H0: P 
20% against the complementary hypothesis H1: P > 20%,
where P is the probability of clinical benefit. The type I error
probability should be <5%. If the true value of P is 35%, the
type II probability should be <20%. An interim analysis was
carried out after 22 patients, and the condition to proceed
was that >5 patients experienced clinical benefit. The total
number of patients needed was 72, and H0 should be
rejected if >19 patients had clinical benefit.
ORR was calculated. KaplaneMeier estimates of PFS
were produced together with 95% confidence interval (CI).
DCR was calculated separately within each mutational sta-
tus group.
Plasma concentration of pazopanib at week 12 was
correlated with DCR using a linear model adjusting for age.
RESULTS
In total, 72 patients were enrolled between 15 March 2012
and 1 October 2014, and their characteristics are shown in
Table 1. The male/female ratio was 47/25, and median age
64.2 years. All 72 patients had demonstrated progression on
imatinib, and after that also on sunitinib. Furthermore, 11
of the patients had also used nilotinib with progression in
all cases. A total of 45 patients had a WHO PS 0, 25 had PS
1, and 2 patients had PS 2. KIT exon 11 was the dominating
site for primary mutation (n ¼ 31), followed by exon 9 (n ¼
13), no detected mutation (n ¼ 11), exon 13 (n ¼ 2), and
Volume 6 - Issue 4 - 2021exon 17 (n ¼ 1). The primary mutation was not available for
14 patients. No patients had a known mutation in the
PDGFRA gene.
Two patients died before week 12 of treatment, and five
further patients were not assessable at week 12; three of
them did not show up for a visit after report of disease
progression, one did not come because of some intercur-
rent disease, and one wished to end study participation. The
DCR after 12 weeks was 32/72 (44%), with 2 PRs and 30 SD.
The median PFS was 19.6 weeks (95% CI 12.6-23.4 weeks)
(Figure 1). No statistically significant differences were found
related to KIT exon 9 or 11 mutations (Figure 2).
Research samples for measurement of plasma pazopanib
concentration at week 12 were obtained from 54/72 (75%)
patients. The concentration had a significant positive cor-
relation with disease control, when a linear model adjusting
for age was applied (R ¼ 6.758, 95% CI 0.216-13.300, P ¼
0.0432) (Figure 3). Hence, there is evidence that plasma
concentration may have an impact on disease control,
which has also earlier been indicated for imatinib.13
Removing one single observation, however, makes the
relation non-significant (R ¼ 4.991, 95% CI 1.048-11.029,
P ¼ 0.1032), which still makes the finding somewhat
provisional.
The toxicity was moderate and manageable, with no toxic
deaths. The most common adverse events of grade 3-4 were
hypertension in 28%, and diarrhoea and fatigue in 8% each
(Table 2). A large number of different low-grade (1-2) tox-
icities occurred (not shown). Notably, however, there were
no patients experiencing grade 3-4 hand-foot syndrome; 14
grade 1 and 3 grade 2.DISCUSSION
With 72 patients with advanced GIST enrolled for third-line
or fourth-line pazopanib treatment, to our knowledge, this
trial had the highest number of GIST patients treated with
this drug to date.
The trial shows a DCR according to RECIST 1.1 at 12
weeks of 44% in patients with truly progressive disease at
the time of enrolment, which demonstrates that pazopanib
may be a good treatment alternative in the third line. The
median PFS of 19.6 weeks is quite similar to the result in
the GRID trial with regorafenib, described as 4.8 months.5
The toxicity seems to be favourable compared with regor-
afenib in the GRID trial (e.g. grade 3-4 hand-foot skin re-
actions in 0% for the present trial and 20% in the GRID
trial). Hypertension grade 3-4 was slightly more common for
pazopanib in PAGIST (28%) than for regorafenib in GRID
(23%).
All mutation analyses were carried out at highly experi-
enced laboratories. There was no difference with respect to
outcome based on primary mutation. This is not surprising,
since the progression of advanced GIST in later treatment
lines is driven by secondary mutations in KIT.
The plasma concentration of pazopanib was measured at
week 12 and gave an indication that lower concentrations
may give a worse disease control, but there is clearhttps://doi.org/10.1016/j.esmoop.2021.100217 3
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Figure 1. Progression-free survival.
CI, confidence interval.
ESMO Open M. Eriksson et al.uncertainty since removing one single observation makes
the correlation non-significant.
The single-arm design of this trial was motivated by the
fact that patients with a progressive GIST, which was a main
eligibility criterion for the study, have an extremely poor PFS
without any TKI at all. Thus, the placebo arm in the pivotal
trial for the use of sunitinib in second line in GIST had a
median PFS of only 1.5 months, despite enrolling patients
with imatinib intolerance only.4 The RIGHT trial comparing
imatinib rechallenge with placebo, with so called best
supportive care (BSC) in both arms, in patients with pro-
gression or intolerance on second-line sunitinib, showed a
median PFS for the placebo arm of 0.9 months only.14 The
GRID trial on regorafenib also demonstrated a median PFS
of 0.9 months for the placebo arm.5 In the PAZOGIST trial,
15% in the BSC arm showed no progression after 4 months,
but the trial allowed patients with intolerance for imatinib
and/or sunitinib to be enrolled, which may include patients
with a rather indolent course.8 Even recently, the new TKI
ripretinib was approved in the USA based on a placebo-
controlled trial with a PFS for the placebo arm of 1.0
month.15 Some of these placebo-controlled trials have a
cross-over design for patients in the placebo arm, but in all
studies, there are patients obviously too poor to benefit4 https://doi.org/10.1016/j.esmoop.2021.100217from this possibility. Bearing this in mind, further trials in
advanced GIST, controlled by placebo or BSC, must be
discouraged as ethically doubtful.
Furthermore, in most trials in advanced GIST, eligibility
has included intolerance for last TKI as an acceptable
alternative to progressive disease. However, intolerance is
seldom clearly defined. Since it is well known that the
disease in many patients on TKIs for advanced GIST may be
controlled by reduced doses in case of intolerance on full
dose, there is an obvious risk that patients may be switched
to a less active TKI based on intolerance before step-wise
dose reduction to an acceptable dose has been carried
out (e.g. from imatinib to sunitinib). Furthermore, when
eligibility in a trial includes intolerance, it may be tempting
to enrol patients with moderate toxicity. For this reason, the
present PAGIST trial claimed progressive disease on the
highest tolerable dose of all the used TKIs, whereas intol-
erance only was not enough. Thus, the trial tested pazo-
panib in patients truly refractory to earlier lines of
treatment.
In summary, this phase II trial on pazopanib as third-line
treatment in advanced and truly progressive GIST demon-
strates a meaningful activity in the same order as regor-
afenib, and with a favourable tolerance.Volume 6 - Issue 4 - 2021
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Figure 3. Plasma concentration of pazopanib 12 weeks after treatment start correlated with disease control when applying a linear model adjusting for age.
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Table 2. Grade 3 or 4 adverse events according to Common Terminology






Abdominal pain 4 (5.6)
Proteinuria 3 (4.2)
Alkaline phosphatase increase 2 (2.8)
Nausea 2 (2.8)
Bilirubin increase 1 (1.4)
Abdominal distension 1 (1.4)
Neutropenia 1 (1.4)
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